2017
DOI: 10.29074/ascls.30.4.207
|View full text |Cite
|
Sign up to set email alerts
|

Suppression of Antimicrobial Resistance in MRSA Using CRISPR-dCas9

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
13
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 21 publications
(15 citation statements)
references
References 11 publications
(10 reference statements)
2
13
0
Order By: Relevance
“…1A ). CRISPRi has been successfully established in bacterial species such as Escherichia coli ( 20 ), Bacillus subtilis ( 21 ), Streptococcus pneumoniae ( 22 ), Staphylococcus aureus ( 23 26 ), and Lactococcus lactis ( 27 ). Note that CRISPR-based tools have been used in lactobacilli previously.…”
Section: Introductionmentioning
confidence: 99%
“…1A ). CRISPRi has been successfully established in bacterial species such as Escherichia coli ( 20 ), Bacillus subtilis ( 21 ), Streptococcus pneumoniae ( 22 ), Staphylococcus aureus ( 23 26 ), and Lactococcus lactis ( 27 ). Note that CRISPR-based tools have been used in lactobacilli previously.…”
Section: Introductionmentioning
confidence: 99%
“…This strategy leads to plasmid curing, thereby reducing the prevalence of antibiotic-resistant bacteria [11,[21][22][23][24][25][26][27]. Researchers have also utilized a catalytically "dead" Cas9 (dCas9) to suppress transcription of the methicillin resistance gene mecA in Staphylococcus aureus [28] and the class 1 integron in Escherichia coli, which is associated with a variety of resistance genes [29]. The diversity of these applications demonstrates how valuable CRISPR/Cas systems could become in the fight against rapidly emerging MDR bacteria.…”
Section: Crispr Antimicrobials: An Overviewmentioning
confidence: 99%
“…Results of the experiments have shown a 77% decrease in gene expression in CRISPR-treated samples; however, 77% was not sufficient to make MRSA clinically susceptible to β-lactam antibiotics. The CRISPR–dCas9 system applied in these experiments did not kill the bacteria, which makes it a viable option for treatment against antibiotic-resistant bacteria [ 91 ]. In a different study, Kang et al introduced a nonviral delivery method for CRISPR (Cr-Nanocomplex), based on a polymer-derivatized Cas9 protein and sgRNA nanocomplex targeting mecA —a major antibiotic resistance gene involved in MRSA.…”
Section: Crispr Applications—antibiotic Resistant Bacteriamentioning
confidence: 99%